Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	816.40B
Revenue (ttm)	241.80B
Net Income (ttm)	21.84B
Shares Out	7.02M
EPS (ttm)	3,398.79
PE Ratio	34.22
Forward PE	34.12
Dividend	1,200.00 (1.00%)
Ex-Dividend Date	Sep 29, 2025

Volume	70,218
Average Volume	35,744
Open	119,300
Previous Close	119,700
Day's Range	115,900 - 120,100
52-Week Range	112,100 - 182,700
Beta	0.26
RSI	38.78
Earnings Date	Mar 20, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.